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The effect of macrophage-targeted
interventions on blood pressure  a systematic
review and meta-analysis of preclinical studies
ELIANE F.E. WENSTEDT, THIRZA J. VAN CROONENBURG, BERT-JAN H. VAN DEN BORN,
JAN VAN DEN BOSSCHE, CARLIJN R. HOOIJMANS, and LIFFERT VOGT
AMSTERDAM, AND NIJMEGEN, THE NETHERLANDS
An increasing body of evidence shows a role for macrophages and monocytes (as
their precursors) in hypertension, but with conflicting results with regard to whether
they are protective or harmful. Therefore, we systematically reviewed the effect of
macrophage interventions on blood pressure in animal models, to explore which
factors determine the blood pressure increasing vs. decreasing effect. A search in
PubMED and EMBASE yielded 9620 records, 26 of which were included. Eighteen
studies (involving 22 different experiments (k = 22)) performed macrophage deple-
tion, whereas 12 studies specifically deleted certain macrophage proteins. The
blood pressure effects of macrophage depletion were highly various and directed
toward both directions, as expected, which could not be reduced to differences in
animal species or methods of hypertension induction. Prespecified subgroup analy-
sis did reveal a potential role for the route in which the macrophage-depleting
agent is being administrated (intraperitoneal vs intravenous subgroup difference of
P = 0.07 (k = 22), or P < 0.001 in studies achieving considerable (ie, >50%) depletion
(k = 18)). Along with findings from specific macrophage protein deletion studies—
showing that deletion of one single macrophage protein (like TonEBP, endothelin-B,
EP4, NOX-2 and the angiotensin II type 1 receptor) can alter blood pressure
responses to hypertensive stimuli—the indication that each route has its specific
depletion pattern regarding targeted tissues and macrophage phenotypes sug-
gests a determinative role for these features. These hypothesis-generating results
encourage more detailed depletion characterization of each technique by direct
experimental comparisons, providing a chance to obtain more knowledge on
which macrophages are beneficial versus detrimental in hypertension develop-
ment. (Translational Research 2021; 230:123138)
Abbreviations: a1AMPK = AMP-activated protein kinase; DOCA = deoxycorticosterone ace-
tate; EP4 = prostaglandin E2 type 4 receptor; IL-10 = interleukin 10; i.p. = intraperitoneal; i.v. =
intravenous; L-NAME = L-NG-Nitro arginine methyl ester; NOX-2 = NADPH oxidase 2; PBS =
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phosphate buffered saline; PHD2 = prolyl hydroxylase domain protein 2; PPARg = peroxisome
proliferatoractivated receptor-g; TonEBP = tonicity-responsive enhancer-binding protein
AT A GLANCE COMMENTARY
Wenstedt EFE, et al.
Background
An increasing body of animal studies shows a role
for macrophages in hypertension. However, mac-
rophage depletion leads to blood pressure
increases in some studies, but decreases in others.
In this meta-analysis, we found that the experi-
mental technique used for macrophage deple-
tion—more specifically, the route of
administration of the depleting agent—may be of
importance for determining the blood pressure
effect.
Translational Significance
Since each technique is indicated to have a dis-
tinct depletion pattern in terms of tissues and phe-
notypes, a determinative role for these features is
suggested. Direct experimental comparisons are
however scarce, and highly warranted.
INTRODUCTION
Hypertension is highly prevalent throughout the
world, and is regarded as the most important risk factor
for global mortality.1 Its pathophysiology however, is
still incompletely understood. In the last decades, the
notion that monocytes and macrophages are involved in
hypertension development came forward.2-4 Experimen-
tal hypertension appeared to induce monocyte infiltra-
tion in the vessel wall and organs like the kidney and the
heart,5-7 and monocytes were shown to be increased in
number and activation state in hypertensive animal mod-
els8 as well as hypertensive humans9,10 compared to
healthy controls. Unraveling the causal relation between
monocytes and macrophages and blood pressure regula-
tion is essential for complete understanding of hyperten-
sion pathophysiology and might potentially result in
new therapeutic targets.
To date, however, the involvement of macrophages
and their monocyte precursors (further referred to as
macrophages) in blood pressure regulation remains a
complex matter that is not fully understood.2,3,11 Sev-
eral animal studies have been performed to study the
effect of macrophage depletion on blood pressure.
Intriguingly, some of these studies report a protective
role for macrophages in the development of hyperten-
sion (ie, blood pressure elevation after macrophage
depletion)12,13 while others suggest a detrimental role
(ie, blood pressure decrease after macrophage deple-
tion).14,15 Potential reasons for these distinct outcomes
are uncertain, but may relate to the way depletion is
established.
Several experimental techniques for macrophage
depletion are currently available.16 Nongenetic deple-
tion is relatively straightforward compared to other
methods, of which clodronate liposomes are the most
widely used.16 When the liposomes are phagocytosed
by macrophages, the phospholipid bilayers of the lipo-
somes are degraded by lysosomal phospholipases and
the clodronate (Cl2MBP) is released, which subse-
quently induces apoptosis of the macrophage.17 An
established genetic macrophage depletion model con-
cerns transgenic mice that express the human diphtheria
toxin receptor under the control of the mouse CD11b or
LysM promotor. Since the human diphtheria toxin
receptor is substantially more sensitive to diphtheria
toxin than the mouse receptor, a certain administered
dose of diphtheria toxin can specifically target the cells
expressing the receptor without affecting other cells.16
Besides macrophage depletion models, genetically mod-
ified animal lines have been used to delete certain mac-
rophage receptors or markers in various studies, using
for example a Cre-Lox combination or adoptive transfer
of monocytes from specific knock-out mice.13,14,18-21
To study the role of specific macrophage features in
hypertension development, systematic assessment of
all models reported in literature may help to elucidate
when and why macrophages are beneficial versus when
they are detrimental in hypertension development.2,3,11
In this review, we therefore systematically assessed the
effect of macrophage interventions on blood pressure
in animal models, aiming to (1) explore potential rea-
sons for the opposite effects of macrophage depletion
on blood pressure in different studies and to (2) estab-
lish which macrophage proteins play a role in blood
pressure regulation.
METHODS
Literature search. PubMed and MEDLINE were
searched (until October 2019) for eligible studies. The
electronic search strategy was designed by 2 authors
(E.W. and C.H.) who were trained and experienced in
systematic review searches for animal studies
(SYRCLE, SYstematic Review Center for Laboratory
animal Experimentation, Nijmegen, The Netherlands),
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and can be found in the Supplemental Material. Addi-
tionally, reference lists of previously published narra-
tive reviews and of included articles were checked for
eligible studies that might have been missed by the
electronic search. All animal species, publication dates,
and languages were included in the search. Reporting
of this review adheres to the PRISMA guidelines.22
The review protocol was registered at PROSPERO and
can be accessed at www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42019150488.
Study selection. In order to be included in this review
all identified references were screened according to the
following eligibility criteria: (1) the study needed to be a
primary animal study with full-text available; (2) the
intervention needed to specifically and systematically
target monocyte/macrophages; (3) blood pressure out-
comes had to be available in the main text or supple-
mental data. The screening process was performed by 2
independent reviewers (E.W. and T.v.C.) and consisted
of 2 phases, the first of which was based on title and
abstract and the second on the full text. Reviews and
conference abstracts were excluded. The review was
separated in 2 parts, with part I focusing on the effect of
macrophage depletion, and part II focusing on the effect
of macrophage-specific phenotype alterations.
Data extraction. Data extraction was done by 2 inde-
pendent reviewers (E.W. and T.v.C). In case of missing
data in the article, authors were contacted to provide
the information. We extracted data on animal species,
animal strain, sex, age, number of animals (in treatment
and control group), details of macrophage intervention
(type of depleting agent, route of administration, dos-
age, timing), effectivity of macrophage intervention (%
reduction in monocytes/macrophages (part I) or %
reduction in the targeted macrophage marker (part II)),
details of hypertension induction (animal model and/or
type of agent, dosage, timing), method of blood pres-
sure measurements, and blood pressure. One study can
involve multiple experiments (k), data were extracted
per experiment. For blood pressure, we extracted the
mean blood pressure after macrophage depletion and
the mean difference after-before macrophage depletion
(if available) for part I, with according standard devia-
tions (SD) and number of animals. For part II, we
extracted the mean blood pressure of the animals with
macrophage-specific deletion of specific markers and
control animals, with according SD and number of ani-
mals. Data not reported numerically were extracted
from graphs using a digital ruler.
Risk of bias assessment. Risk of bias was assessed
using SYRCLE’s Risk of Bias tool by 2 independent
reviewers (T.v.C. and E.W.). Two reporting aspects
were added to this tool, involving “any form of blind-
ing” and “any form of randomization.” Disagreements
were resolved through consensus-oriented discussion
or by consulting a third reviewer (C.H.). Similarity of
treatment and control groups at baseline in studies was
judged by baseline blood pressure (part I) or baseline
age or weight (part II), in which a deviation of §10%
was deemed acceptable.
Data analysis. A quantitative synthesis (meta-analy-
sis) was planned provided there were more than 2 stud-
ies with similar interventions (for at least 2 different
markers in part II). Otherwise, data were summarized
qualitatively. Data were analyzed using Comprehen-
sive Meta-Analysis Version 3.3 (Biostat, Englewood,
NJ 2013) using standardized mean differences (SMD;
Hedges’s g). Effect sizes are presented as the SMD
with 95% confidence intervals (CIs), because of spe-
cies differences and heterogeneity in the data. Data
were pooled using a random-effects model, assuming a
common among-study variance component across sub-
groups (pooled within-group estimates of tau-squared).
Heterogeneity was reported and assessed by the I2 sta-
tistic. When the exact number of animals per group
was unclear (eg, 39 animals), also after repeated
attempt to contact the authors, we used the lowest num-
ber for the meta-analysis. Importantly, the effective-
ness of macrophage depletion may differ substantially
per species and strain, genetic background, and experi-
mental condition.23 Therefore, to avoid statistical pool-
ing of studies too heterogenic, we also performed a
meta-analysis in which only studies with substantial
monocyte/macrophage depletion (>50% reduction)
were included. In both meta-analyses, the studies in the
forrest plots were ordered according to their depletion
effectiveness (using the lowest reduction percentage in
case of differences between monocyte and macrophage
depletion), to be able to pick up patterns resulting from
this feature.
Subgroup analyses. Potential sources of heterogene-
ity were determined a priori, and involved animal spe-
cies, method of macrophage intervention (type of
agent, route of administration), and method of hyper-
tension induction. For subgroup analyses, at least 3
independent experiments had to be present. We
adjusted significance levels according to the Bonferroni
method to account for multiple analyses (P* number of
comparisons).
Publication bias. Publication bias was assessed by
funnel plots and the trim and fill method. Because SE-
based precision estimates cause distortion of SMD fun-
nel plots, 1/xn was used as the precision estimate in
the trim and fill analysis.
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RESULTS
Study selection. A flow-chart of the study selection
process is depicted in Fig 1. A total of 8315 records
was retrieved using the electronic search (after exclu-
sion of duplicates). After initial screening of titles and
abstracts, 52 articles were included for full-text review.
Out of these, 26 studies were included; 18 studies con-
cerning macrophage depletion (part I) and 12 concern-
ing macrophage-specific targeting of certain proteins
(part II) (4 studies were included in both part I and II).
Study characteristics. Details on study characteristics
can be found in Table 1 (part I)12-15,20,24-35 and Supple-
mental Table 3 (part II).13,14,18-21,33,36-40 Of the 18
macrophage depletion studies (part I), 9 studies
involved rat models, 8 involved mouse models, and
one study involved both. The majority of studies (15 of
18) used clodronate liposomes as a macrophage deple-
tion agent, other methods included administration of
diphtheria toxin to a transgenic mouse model (2 stud-
ies) or administration of gemcitabine or anti-Gr1 (one
study). Most studies used liposomes filled with phos-
phate buffered saline (PBS) as a control treatment. The
most used methods of hypertension induction were
angiotensin-II administration (6 studies) and salt load-
ing (5 studies). All studies measured blood pressure in
a time period of minimally 1 week, with the exception
of one study that measured blood pressure until day 3
of the experiment (Falkenham et al). The effectivity of
macrophage depletion differed between studies, rang-
ing from 40% to 90%.
For part II, all 12 studies used mice as the animal
model of choice. Overall, the effect of deletion of 11
different macrophage receptors was investigated in
these studies. The most used method of hypertension
induction was angiotensin-II administration with or
without the addition of L-NAME (2 studies and 5 stud-
ies, respectively). Ten studies used Cre-Lox recombi-
nation to delete specific macrophage markers or
receptors. The mice expressed Cre recombinase under
the control of either the LysM promotor (8 studies) or
the CD11b promotor (1 study) or the CX3CR1 promo-
tor (1 study). Two studies used adoptive transfer of
monocytes of specific knock-out mice (Shah et al:
adoptive transfer with myeloid derived suppressor cells
from NOX2/ mice; Wenzel et al: adoptive transfer
with monocytes from Agtr1/ and gp91phox/y
mice). The effectivity of deletion of the targeted pro-
teins in macrophages differed between studies, ranging
from 60% to 98% (Supplemental Table 3).
Risk of bias. Fig 2A+B (part I) and Fig 2C+D (part II)
show the risk of bias assessment of the 26 included
studies. Overall, several aspects of the SYRCLE risk of
bias tool had to be scored unclear due to missing infor-
mation regarding experimental details. For example, it
was generally unclear whether the group allocation
was blinded, the animals were housed randomly, and
whether or not outcome assessment was blinded. Two
reporting items were added to the SYRCLE risk of bias
tool, with 6 of 18 (part I) and 3 of 12 (part II) studies
reporting randomization at any levels, and 8 of 18 (part
I) and 4 of 12 (part II) studies reporting blinding at any
level.
Quantitative synthesis of results (part I). For part I, all
18 studies could be included in the meta-analysis regard-
ing the absolute blood pressure after macrophage inter-
vention, involving 22 experiments (k = 22). There were
not enough studies that reported the mean difference
(SD) in blood pressure after-before the macrophage
intervention to pool the data (k = 1). The direction of the
9620 Records idenfied through 
database searching

























52 Full-text arcles assessed for 
eligibility




26 Studies included in qualitave 
synthesis
18 Studies included in quantave
synthesis (meta-analysis)
Fig 1. Flow diagram of screening process. The screening process
was performed by 2 independent reviewers and consisted of 2 phases,
the first of which was based on title and abstract and the second on
the full text. Only studies with macrophage-targeted interventions
that did not have clear side effects (eg, on other types of immune
cells or tissues) were included.
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Table 1. Summary of study characteristics (part I)
Study (PMID) Species and
model
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i.v. Weekly Salt 50% splenic
mK, 50%
monocytes**
Huang et al 1
(29867533)
M; C57BL/6 M 6 wk 8 8 CL
liposomes
PBS liposomes 16.7 mg/kg i.v. Every 3 days Ang II 62% kidney mK,
70%
monocytes
Huang et al 2
(29867533)
R; Dahl SS M 6 wk 8 8 CL
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Shah et al 1
(26294657)
M; RFP M 810 wk 615 615 gemcit-
abine
Saline 10.7 g/kgz i.p. Weekly (2 in 1st
week)
Ang II 90% circulating
MDSCs
Shah et al 2
(26294657)
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Species: M, mouse. R, rat. Sex: M, male. F, female. N (T): N (treatment group). N (C): N (control group). CL, clodronate. DT, diphtheria toxin. PBS, phosphate buffered saline. i.p., intraperitoneal. i.v.,
intravenous.
*From authors’ correspondence.
yFirst dose between brackets (if deviating from rest of the doses).
zAssuming a weight of approximately 20 g for each mouse.
**Not included in meta-analysis 2 because of 50% reduction.
































effect of macrophage depletion on blood pressure dif-
fered considerably between studies, as expected (SMD
(95% CI) 0.071 (0.8330.691); P= 0.86; I2 91%;
k = 22), also when only including studies that achieved
substantial (>50%) monocyte/macrophage reduction
(0.221 (0.9770.535); P= 0.57; I2 89%; k = 18; Sup-
plemental Figs 1 and 2). Prespecified subgroup analyses
did not reveal statistically significant differences
between animal species (rats vs mice; P= 0.92), hyper-
tension induction methods (salt loading vs. angiotensin-
II vs other; P= 0.58), or route of administration,
although the latter showed a trend toward a difference
(P = 0.07) (intraperitoneal (i.p.): SMD (95% CI) 0.776
(0.2531.806); P= 0.14; I2 85%; k = 11, intravenous
(i.v.): 0.850 (2.0600.359); P= 0.17; I2 93%; k = 8;
Fig. 3 and 5, A). In the analysis only including studies
that achieved substantial (>50%) monocyte/macro-
phage reduction (k = 18), i.p. administration of the mac-
rophage depleting agent leads to a blood pressure
increase (SMD (95% CI) 1.405 (0.4722.338); P=
0.003; I2 69%; k = 8), and i.v. administration results in a
blood pressure decrease (SMD (95%CI) 1.607
(2.576 to 0.638; P= 0.001; I2 88%; k = 7; P< 0.001
for subgroup differences; Fig 4 and 5, B). The subgroup
analyses on animal species (P= 0.40) and on method of
hypertension induction (P = 0.93) did not reveal any dif-
ferences (Fig 5, B).
Publication bias. Assessment of the funnel plot sug-
gested no publication bias (Supplemental Fig 3).
Qualitative synthesis of results (part II). In the 12 studies
that deleted specific macrophage proteins, a total of 10
different proteins were targeted. Since of only one
(mineralocorticoid receptor) there were more than 2
independent experiments available, a qualitative rather
than quantitative synthesis was carried out, summa-
rized in Table 2. Of the total of 10 macrophage pro-
teins, 3 were identified to have a protective role against
hypertension development (ie, blood pressure increase
with deletion), including TonEBP, endothelin-B, and
EP4. NOX-2 and the angiotensin II type 1 receptor on
the other hand, worsen hypertension, shown by attenu-
ated angiotensin-II-induced blood pressure increases
with adoptively transferred NOX-2/ or angiotensin-
II receptor type I/y monocytes compared to wild type
monocytes. In contrast, NOX-2-negative myeloid-
derived suppressor cells (involving monocyte subtypes
but also granulocyte subtypes), increase blood pres-
sure, indicating a protective role for this receptor in
these cell types (in concordance with their apparent T-
cell suppressive effect). Deletion of the macrophage
mineralocorticoid receptor led to a blood pressure
decrease in 2 studies (Bienvenu et al: L-NAME-
induced hypertension, blood pressure at +4 weeks;
Rickard et al.: DOCA-induced hypertension, blood
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%




Reporng of quality indicators 
Yes Unclear No
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Free of other problems
Free of selecve outcome reporng (reporng)
Random outcome assessment (detecon)
Reporng of drop-outs (arion)
Blinded outcome assessment (detecon)
Random housing (performance)
Blinded group allocaon (selecon)
Groups similar at baseline (selecon)
Random group allocaon (selecon)
Risk of Bias
Low Unclear High
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%




Reporng of quality indicators 
Yes Unclear No
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Free of other problems
Free of selecve outcome reporng (reporng)
Random outcome assessment (detecon)
Reporng of drop-outs (arion)
Blinded outcome assessment (detecon)
Random housing (performance)
Blinded group allocaon (selecon)
Groups similar at baseline (selecon)
Random group allocaon (selecon)
Risk of Bias





Fig 2. Risk of bias assessment. (A, B) Risk of bias assessment of included studies in part I. (C, D) Risk of bias
assessment of included studies in part II. Risk of bias was assessed using SYRCLE’s risk of bias tool by 2 inde-
pendent reviewers.
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pressure at +4 and +8 weeks), but an increase in one
study (Usher et al: salt-induced and L-NAME-induced
hypertension, blood pressure at +2 weeks and +3.5
weeks). Four proteins could not be demonstrated to
have any effect on blood pressure, involving IL-10,
PHD2, a1AMPK, and PPARg (Supplemental Table 3).
DISCUSSION
The divergent and opposite results of macrophage
depletion studies in terms of blood pressure underline
the fine complexity of macrophage functionality in
blood pressure regulation. We identified the route of
administration of macrophage-depleting agents as well
as the extent of macrophage depletion as potential
determinants of the direction of the blood pressure
effect. Together with the observation that specific and
single macrophage proteins determine a blood pressure
elevating vs. lowering effect, this points toward a deci-
sive role for macrophage phenotype—since there are
clear indications that different routes of administration
target distinct tissues and phenotypes.
This has best been investigated for clodronate lipo-
somes. Both i.p. and i.v. clodronate liposomes deplete
macrophages or their precursors in for example the cir-
culation, bone marrow, spleen and liver, but i.p. admin-
istration additionally depletes macrophages in the
peritoneal cavity and (some) lymph nodes. The extent
of macrophage depletion within each organ also dif-
fers; for example for the colon, i.v. administration is
more efficient compared to i.p. administration (90% vs.
50% macrophage depletion).23 With regard to pheno-
type, it becomes more complicated, since (to the best
of our knowledge), this has not been determined with
experiments directly comparing different routes of
Group by
Route of administration
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit
i.p. Martin et al. -2,652 -4,266 -1,038
i.p. Machnik et al. 2010 (1) 1,530 0,645 2,416
i.p. Moore et al. -2,127 -3,385 -0,869
i.p. Machnik et al. 2010 (2) 1,052 0,151 1,952
i.p. Wenzel et al. -1,079 -2,498 0,339
i.p. Machnik et al. 2009 0,933 0,102 1,764
i.p. Ruan et al. 1,928 0,630 3,227
i.p. Czopek et al. (1) 3,527 1,771 5,282
i.p. Czopek et al. (2) 3,114 1,169 5,058
i.p. Shah et al. (1) 1,487 0,285 2,689
i.p. Shah et al. (2) 1,074 0,016 2,133
i.p. 0,776 -0,253 1,806
i.p. (i.v.) Pires et al. -0,080 -0,777 0,616
i.p. (i.v.) Thang et al. -1,950 -3,168 -0,732
i.p. (i.v.) Mui et al. -1,383 -2,656 -0,110
i.p. (i.v.) -1,104 -3,029 0,821
i.v. Fehrenbach et al. 7,309 4,828 9,791
i.v. Kain et al. -0,833 -2,063 0,398
i.v. Huang et al. (1) -3,488 -5,011 -1,965
i.v. Zandbergen et al. -0,441 -1,435 0,554
i.v. Huang et al. (2) -2,269 -3,484 -1,054
i.v. Falkenham et al. 0,402 -0,424 1,229
i.v. Kriska et al. -4,746 -6,230 -3,263
i.v. Shimada et al. -0,885 -1,488 -0,283
i.v. -0,850 -2,060 0,359
-8,00 -4,00 0,00 4,00 8,00
Blood pressure decrease Blood pressure increase
Fig 3. Part I: meta-analysis 1 (including all studies). Data were analyzed using standardized mean differences
(Hedges’s g). Effect sizes are presented as the standardized mean difference (SMD) with 95% confidence inter-
vals, because of species differences and heterogeneity in the data. Data were pooled using a random-effects
model, assuming a common among-study variance component across subgroups (pooled within-group estimates
of tau-squared).
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Group by
Route of administration
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit
i.p. Machnik et al. 2010 (2) 1,052 0,151 1,952
i.p. Wenzel et al. -1,079 -2,498 0,339
i.p. Machnik et al. 2009 0,933 0,102 1,764
i.p. Ruan et al. 1,928 0,630 3,227
i.p. Czopek et al. (1) 3,527 1,771 5,282
i.p. Czopek et al. (2) 3,114 1,169 5,058
i.p. Shah et al. (1) 1,487 0,285 2,689
i.p. Shah et al. (2) 1,074 0,016 2,133
i.p. 1,405 0,472 2,338
i.p. (i.v.) Pires et al. -0,080 -0,777 0,616
i.p. (i.v.) Thang et al. -1,950 -3,168 -0,732
i.p. (i.v.) Mui et al. -1,383 -2,656 -0,110
i.p. (i.v.) -1,078 -2,542 0,386
i.v. Kain et al. -0,833 -2,063 0,398
i.v. Huang et al. (1) -3,488 -5,011 -1,965
i.v. Zandbergen et al. -0,441 -1,435 0,554
i.v. Huang et al. (2) -2,269 -3,484 -1,054
i.v. Falkenham et al. 0,402 -0,424 1,229
i.v. Kriska et al. -4,746 -6,230 -3,263
i.v. Shimada et al. -0,885 -1,488 -0,283
i.v. -1,607 -2,576 -0,638
-8,00 -4,00 0,00 4,00 8,00
Blood pressure decrease Blood pressure increase
Fig 4. Part II: meta-analysis 2 (including only studies achieving substantial (50%) macrophage depletion).
Data were analyzed using standardized mean differences (Hedges’s g). Effect sizes are presented as the stan-
dardized mean difference (SMD) with 95% confidence intervals, because of species differences and heterogene-
ity in the data. Data were pooled using a random-effects model, assuming a common among-study variance
component across subgroups (pooled within-group estimates of tau-squared).
Fig 5. Summary estimates of subgroup analysis of meta-analysis 1 (A) and 2 (B). A. Meta-analysis 1 (k = 22).
There was no significant difference between subgroups on species (P = 0.92) or method of hypertension induc-
tion (P = 0.58). There was a trend toward a difference between subgroups on route of administration (P = 0.07).
B. Meta-analysis 2 (k = 18). There was no significant difference between subgroups on species (P = 0.40) or
method of hypertension induction (P = 0.93). There was a significant difference between subgroups on route of
administration (P < 0.001). i.p., intraperitoneal; i.v., intravenous; SMD, standardized mean difference; SEM,
standard error of the mean.
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administration using the same agent. Ferenbach et al
did reveal important information, by showing consider-
able differences between i.v. clodronate liposomes and
i.p. diphtheria toxin in CD11b-diphtheria toxin receptor
mice.41 I.v. administration of clodronate liposomes left
“M2-like” CD206+ renal macrophages unaltered, in
contrast to i.p. administration of diphtheria toxin. Also,
i.p. diphtheria toxin had a more profound effect on cir-
culating monocytes and renal macrophages. Only i.v.
clodronate liposomes appeared to protect against kid-
ney damage. This is in concordance with the finding in
the present review that also in terms of blood pressure,
the beneficial effect is only achieved with i.v. adminis-
tration of clodronate liposomes and not with i.p. Poten-
tially, but speculatively, macrophage depletion is only
beneficial to a certain extent, ensuring that enough
“beneficial” macrophages are left behind. Importantly,
different types of macrophage-depleting agents almost
certainly target distinct tissues and phenotypes (eg,
clodronate liposomes vs diphtheria toxin, the most
used methods in this review), which raises the question
whether these studies should be pooled at all. Since the
goal of all these interventions is similar, that is,
“macrophage depletion,” we chose to start with a full
overview including all studies. While this imposes a
risk of comparing pears and oranges, it can actually
also reveal important information by subsequently
looking into blood pressure effects of subgroups. This
full overview also included one study that used gemci-
tabine and anti-Gr1 as a depletion agent, which should
be noted is the most precarious to include since these
agents target myeloid-derived suppressor cells, which
involve monocyte subtypes but also granulocyte sub-
types.20,42 However, since actually probably none of
the macrophage-depletion methods currently available
are perfectly specific for macrophages (discussed fur-
ther below in more detail), and for example for gemci-
tabine there are indications that in fact preferentially
monocytes are targeted,43 we chose to include this
study, while checking that repeating the analyses
excluding this study did not materially affect our
results. We emphasize that pre-specified subgroup
analysis on type of agent could not be performed due
to the limited amount of studies using other methods
than clodronate liposomes. Control treatments mainly
consisted of liposomes filled with PBS (for the majority
Table 2. Role of macrophage proteins in blood pressure regulation (part II). A qualitative synthesis is depicted for the 6
macrophage proteins that were identified to play a role in hypertension development, as derived from the 12 studies
included in part II of this review
Macrophage proteins Proposed mechanism
Protective against hypertension development
Endothelin B receptor13 The macrophage endothelin B receptor enables endocytosis of
endothelin-1 (vasoconstricting agent) by macrophages
TonEBP21 Macrophage TonEBP regulates VEGF-C-mediated lymphangio-
genesis, which appears to protect against excessive salt-
induced blood pressure rises (albeit by mechanisms not fully
elucidated)
PGE2 type 4 (EP4)
18 COX-2 via EP4 plays a role in VEGF-C production and lymphangio-
genesis
PGE2 type 4 (EP4) deletion! “M1” " “M2” #! increased renal
infiltration of T-cells, neutrophils, macrophages
Contributing to hypertension development
Angiotensin II type 1 receptor14 The angiotensin II type 1 receptor contributes to reactive oxygen
species formation and vascular dysfunction
NOX-2 (NADPH oxidase)14 The NOX-2 pathway contributes to reactive oxygen species for-
mation and vascular dysfunction
Adoptive transfer with NOX-2 depleted monocytes does not
aggravate the angiotensin-II-induced blood pressure increase,
whereas adoptive transfer of wildtype monocytes does[14]*
* Adoptive transfer with NOX-2 depletedmyeloid-derived sup-
pressor cells aggravates the angiotensin-II-induced blood pres-
sure increase20
Protective/contributing to hypertension development
Mineralocorticoid receptor36-38 Contributes to hypertension36,37
Mineralocorticoid receptor! “M1” " “M2” #
Protective against hypertension*38
*but contributing to cardiac hypertrophy, fibrosis, and vascular
damage
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of studies that used clodronate liposomes) which seems
to be a good control experiment. Although it has been
suggested that also PBS liposomes may temporarily
inhibit macrophage function,17,23 Falkenham et al
directly assessed the effect of PBS liposomes on differ-
ent leukocyte subsets and did not observe indications
for this24. In the case that an inhibitory effect of PBS
liposomes on macrophages does exist, this may have
resulted in an underestimation of the blood pressure
effect in our meta-analysis rather than an overestima-
tion (since substantial macrophage depletion would be
compared to subtle macrophage depletion instead of no
macrophage depletion at all).17
The notion that the phenotype of macrophages is
determinative is supported by Harwani et al, who
describes that in general, pro-inflammatory (M1-like)
macrophages are the culprits in hypertension while
anti-inflammatory (M2-like) macrophages are able to
reduce blood pressure. Amongst others, spontaneously
hypertensive rats are shown to have higher “M1/M2”
ratios than normotensive Wistar-Kyoto rats, and after
reducing this ratio by heme oxygenase-1 induction,
blood pressure decreases. On the other hand, this
notion does not exclusively comply with the effects of
the described receptors in this review. For example,
despite its beneficial role (shown by aggravated blood
pressure increases with deletion), TonEBP has been
associated with the “M1” phenotype rather than the
“beneficial” “M2” phenotype.44,45 Of note, the fact that
macrophages are not static but rather highly versatile
and able to switch between phenotypes should be taken
in consideration when assessing the role of macrophage
phenotypes and hypertension.46
As said above, an essential remark with regard to
both macrophage depletion studies and macrophage-
protein alteration studies is that probably none of the
methods used are perfectly specific for macro-
phages.16,47 Theoretically, clodronate liposomes may
additionally target neutrophils and dendritic cells—in
concordance with their ability for phagocytosis—
although in practice, several studies demonstrated no
effect on circulating neutrophil counts15,24,41,48 or
(renal and splenic) dendritic cells.17,41 With diphtheria
toxin, it depends on to which promotor the receptor is
coupled, which involved LysM14 and CD11b13 in the
studies in this review. LysM is also expressed in granu-
locytes and some dendritic cells, and CD11b is
expressed by all myeloid cells. Indeed, there was a
reduction in circulating dendritic cells with CD11b-tar-
geted depletion, although no reduction in neutrophils
was observed with both methods.13,14 When more
immune cells are targeted, adoptive transfer of each
type can help to distinguish cell-specific roles. Wenzel
et al14 and Czopek et al13 performed adoptive transfer
of CD11b+Gr1+ monocytes and were able to confirm
that the observed effect of depletion was truly due to
monocytes and not to other potentially depleted cell
types. However, dendritic cells remain a relatively
ignored cell type, despite that they are targeted with
many macrophage depletion methods and there is
increasing evidence that they play a role in blood pres-
sure regulation as well. For example, when dendritic
cells are triggered by in vitro sodium excess and subse-
quently adoptively transferred into naive mice, hyper-
tension is aggravated49, with mechanisms likely
involving promotion of renal oxidative stress, inflam-
mation, and fluid retention.50-52 Also, besides the mac-
rophage depletion methods used in the studies that
could be included in this review, more (and newer)
methods exist and evolve rapidly. A detailed overview
is given by other authors16,47,53 and involves among
others macrophage Fas-induced apoptosis and
CX3CR1-DTR models. Taken together, the potential
role of other possibly depleted immune cell types than
macrophages with each method needs to be kept in
mind, and further scrutinized.
The question remains which mechanisms underlie the
relation between macrophages and hypertension. Protec-
tive actions that have been currently identified involve
clearance of vasoconstricting agents (endothelin-1),13
induction of lymphangiogenesis,12,18,21 and suppression
of T-cell activation,20 but many more may be yet undis-
covered. Cytokine excretion is assumed to have a key
role in the harmful effects of macrophages and hyperten-
sion, leading to vascular dysfunction and renal sodium
retention. Specifically, typical “M1” or pro-inflamma-
tory macrophage cytokines like TNF-a and IL-1b have
been implicated in the development of hypertension,54
supporting the idea of macrophage phenotype as a deter-
minative feature. The process of clinical translation is
ongoing, with the CANTOS trial showing a beneficial
effect of anti-IL-1b on cardiovascular disease but not on
blood pressure.55,56 Also, the effect of anti-TNF-a on
blood pressure is not univocal in humans.57-60 Interpre-
tation of negative findings with regard to the presumed
importance of inflammation in hypertension is hampered
by the lack of sufficiently precise characterization of
inflammation, which is still a broad term encompassing
a multiplicity of distinct pathways.61 A detailed narra-
tive description of underlying mechanisms of macro-
phages and hypertension as well as the role of cytokines
fall beyond the scope of this review, and for this we refer
to several comprehensive literature reviews from other
authors.54,62-66 It may be pointed out that, besides having
a causal role in hypertension development, monocytes
and macrophages can also be affected as a consequence
of hypertension, subsequently attenuating or worsening
further blood pressure increases.4
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Although our literature search involved all animal
species, the included studies in the present review only
involved rats and mice. Separating rat studies from
mouse studies did not result in a clear distinction in out-
come. Mouse and rat strains were too variable to per-
form subgroup analyses on. The immune system of rats
and mice bear some important differences compared to
humans, complicating translation of our results to the
human hypertension setting.67 Among others, lympho-
cytes are the most abundant leukocytes in rats and mice,
while in humans neutrophils form the majority. For
translation to the human situation, human haemato-lym-
phoid system mice may be an interesting alternative,
although they involve quite complicated models and
some have poor reconstitution of mononuclear phago-
cyte system cell types.16 Also complicating translation
to the human situation, is the lack of existence of a per-
fect animal model for primary human hypertension (ie,
the most abundant form of hypertension in humans),
largely due to the still incomplete pathophysiological
knowledge of primary hypertension. Each experimental
model of hypertension comes with its own pitfalls and
advantages, which has been reviewed in detail by other
authors.68 Our meta-analysis did not reveal considerable
differences in macrophage depletion between salt-
induced hypertension and angiotensin-II-induced hyper-
tension; other methods like L-NAME or endothelin-I
administration were not applied in enough included
studies to reliably compare.
In humans, the role of macrophages in blood pres-
sure regulation remains difficult to study. Among the
first evidence in humans, Czopek et al demonstrated
that blood pressure increased more in vasculitis
patients who received a treatment that also affected
monocytes and macrophages (cyclophosphamide)
compared to patients who received a treatment without
an effect on monocytes and macrophages (mycopheno-
late mofetil).13 Furthermore, a salt-sensitive blood
pressure increase in 11 healthy human volunteers was
shown to coincide with an increased pro-inflammatory
monocyte phenotype (increased CCR2 expression) and
macrophage phenotype (increased HLA-DR expression
and reduced CD206 expression; and increased pro-
inflammatory cytokine secretion in vitro).69 Successful
translation to humans, however, requires very specific
interventions (since general macrophage interventions
are unfeasible), which necessitates more detailed
knowledge on when and which macrophages are pro-
tective vs. harmful in hypertension development.
Roughly, there may be 2 general types of approach
for future studies (Table 3). The first approach, total
macrophage depletion (reviewed in part I), was the
major starting point of this research area and signifi-
cantly contributed to the knowledge on macrophages
and hypertension. However, as this review points out,
major but also subtle differences exist between differ-
ent methods (and even potentially between different
routes of administration of the same agent), leading to
opposite effects on blood pressure in some cases.
Rather than regarding this as a nuisance, future direct
comparisons that closely characterize targeted pheno-
types/locations with each depletion method along with
its effect on blood pressure can shed more light on
when and which macrophages are beneficial vs. detri-
mental in hypertension development (for now, no
definitive conclusion can be made yet since there is a
paucity of direct comparisons). The second approach
consists of targeting specific macrophage proteins
(reviewed in part II). Mechanistically, this approach
may be more interesting, and therefore provides a suit-
able way to obtain more knowledge on pathophysiol-
ogy. However, since an abundance of macrophage
proteins exists, this approach may be complementary
to the first approach. From the proteins that are cur-
rently identified, it can be deduced that the pro-lym-
phangiogenic function of macrophages may be
important for protection against hypertension, and that
pro-inflammatory phenotypes contribute to hyperten-
sion. Especially pro- vs. anti-inflammatory is still a
broad term, and should be reduced to specific pro-
cesses. With each approach, potential side effects or
off-target effects should be closely scrutinized, as well
as potential differences in hypertension induction
methods (preferentially making use of more than one
type of induction).
The main strength of this review is that we are—to
the best of our knowledge—the first to address this
issue in a systematic manner. The impact of systematic
reviews of animal studies is increasing because of their
value in pointing out flaws in methodologic quality in
current animal research and improving translation to
clinical care by specifically uncover directions for
future research, amongst others.70-72 Nevertheless, cer-
tain limitations need to be considered. It should be
emphasized that our finding with regard to the rele-
vance of the route of administration of macrophage
depleting agents, derived from subgroup analysis, is
hypothesis-generating rather than hypothesis-testing,
especially since certain important prespecified sub-
group analyses (ie, on type of agent) could not be per-
formed.71 However, the hypothesis-generating nature
of this meta-analysis does guide future research in this
area. For instance, our results warrant a direct compari-
son between different macrophage depleting techni-
ques along with more close characterization of
depleted phenotypes and tissues. Second, there was
substantial heterogeneity between studies. However,
heterogeneity in animal research is expected due to the
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explorative nature of most studies, and, exploration of
sources of heterogeneity can even be regarded as one
of the most added values in meta-analyses of animal
studies.71 Among others, the large differences in effec-
tiveness of macrophage depletion between studies may
be an important contributor to the large heterogeneity
that was observed between studies in this meta-analy-
sis. To address this, we performed an analysis that
excluded studies reporting 50% or less monocyte or
macrophage reduction, but the chosen cut-off is arbi-
trary. This analysis does reveal that the extent of mac-
rophage depletion may also determine the effect on
blood pressure, since the studies with less substantial
depletion appeared to have divergent effects. There-
fore, the extent of macrophage depletion in the circula-
tion as well as in different tissues needs to be
specifically considered and measured (and ideally,
compared) in future experiments. Third, the risk of
bias of the included studies was scored unclear in the
majority of studies due to poor reporting of essential
methodological details. Last, and perhaps most impor-
tantly, the fact that macrophage interventions are not
100% specific and may also target other immune cell
types (mostly neutrophils and dendritic cells), deserves
consideration in making definitive conclusions, despite
that we were conservative with regard to selection of
eligible interventions. We excluded depletion methods
that were shown to have very clear off-target effects on
tissues or other subsets of immune cells (besides den-
dritic cells, which may be targeted with every method
currently available).16,47,53 Excluded interventions
involve for example altered vascular development with
monocytopenic macrophage colony stimulating factor-
deficient osteopetrotic mice (op/op),73 endothelial
alterations with CCR2 knockout mice,74 or interven-
tions targeting macrophage phenotype by administra-
tion of agents that can have a variety of side effects.
Also, interventions with antibodies targeting receptors
(eg, CCR274 or CD161a75) or cytokines (eg, IL-676 or
CCL2/MCP-174) were deemed too unspecific, since
Table 3. Hypotheses generated by the results of this systematic review. Motivations for each hypothesis are given, and sug-
gestions are made for future studies
Hypotheses generated Based on Suggestions for future hypothesis-
testing research
i) pro-inflammatory* macrophage




*this may not necessarily mean
phenotypes associated with the
classical “M1” vs “M2” phenotype
1) i.v. administration of macrophage
depleting agent
! lowers blood pressure
! is suggested to preferentially
target pro-inflammatory
phenotypes
2. i.p. administration of macro-
phage depleting agent
! increases blood pressure
! is suggested to have amore
rigorous effect on all phenotypes
2) Deletion of one singular macro-
phage protein can change the
blood pressure response to hyper-
tension induction
- Direct comparisons between i.v.
and i.p. administration in terms of
targeted macrophage phenotype
and blood pressure
- Targeting of specific macrophage
proteins according to groups of
mechanistic processes (eg, lym-
phangiogenesis, pro-inflammatory
priming, clearance of vasocon-
stricting agents) to uncover under-
lying pathophysiology.
ii) location of macrophages may
determine their role in blood pres-
sure regulation
Opposite blood pressure effect
between i.v. and i.p. administration
of macrophage depleting agent,
along with indications for different
depletion patterns in terms of tar-
geted tissues.
Direct comparisons between i.v. and
i.p. administration in terms of tar-
geted tissues and blood pressure.
All studies need to report macro-
phage reduction in several tissues.
iii) the extent/rigour of macrophage
depletion might determine the
effect on blood pressure
1) selection of studies based on the
extent of macrophage depletion
affected the results (studies show-
ing less than <50% depletion
appeared to have divergent
results)
2) i.p. seems more rigorous than i.v.;
potentially also beneficial (ie, anti-
inflammatory) macrophages are
being targeted
Direct comparisons between differ-
ent extents of macrophage deple-
tion and their associated effect on
blood pressure. All studies need to
report the percentage of circulat-
ing monocyte and tissue macro-
phage (preferably several tissues)
reduction.
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most receptors and cytokines are either present on or
produced by more immune cells than solely monocytes
or macrophages.75 Although the choice on in- versus
exclusion for specific macrophage depletion techniques
was done with great caution by 2 independent authors
(as described above), this choice may not be black and
white, since specificity of methods is often not
completely known and may even differ between differ-
ent reports or with new insights. In general, it should
be noted that only 2 of the 26 included studies com-
prised female animals. Since there is evidence for con-
siderable differences in the immune system77,78 and
hypertension68,79 between sexes, as well as for example
for the extent of salt sensitivity,80 this substantially
hampers translation to women and needs to be
addressed in future studies.
In conclusion, the effect of macrophage depletion on
blood pressure is highly divergent between studies,
which we could not trace back to differences in animal
species or methods of hypertension induction. Our
meta-analysis does suggest a potential role for differen-
ces in experimental techniques, like the route of admin-
istration of the macrophage depleting agent. Rather
than regarding this as a nuisance, characterizing the
effects of each technique along with its effect on blood
pressure provides a chance to obtain more knowledge
on when and which macrophages are beneficial vs. det-
rimental in hypertension development. The fact that
each route of administration has a distinct depletion
pattern in terms of targeted phenotype and tissues,
together with the observation that deletion of one sin-
gle macrophage protein can alter blood pressure
responses to hypertensive stimuli, supports the idea of
a determinative role for macrophage phenotype. More
comprehensive characterization of targeted macro-
phage phenotype as well as potential off-target effects
of distinct macrophage depletion methods is warranted,
as it can help to disentangle the role that macrophages
have in blood pressure regulation.
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